Genesys Capital adds Sunnybrook, UHN to Canadian life sciences seed fund
What's the deal? Genesys CapitalDealroom has a profile for this one. Try Dealroom →, a Canadian life sciences venture firm, has reached a second close of its Genesys University Seed Fund, bringing in Sunnybrook Health Sciences CentreDealroom has a profile for this one. Try Dealroom → and University Health Network (UHN)Dealroom has a profile for this one. Try Dealroom → as hospital partners. The fund backs pre-seed and seed rounds for life science companies emerging from Canadian universities and hospitals.
Who else is in? The two hospitals join a first-close roster that included the University of TorontoDealroom has a profile for this one. Try Dealroom →, McMaster UniversityDealroom has a profile for this one. Try Dealroom →, Venture OntarioDealroom has a profile for this one. Try Dealroom →, the Temerty GroupDealroom has a profile for this one. Try Dealroom →, and RBCDealroom has a profile for this one. Try Dealroom →. The fund's size was not disclosed.
What's the endgame? Genesys says the fund was built to close a persistent gap in Canada's innovation economy: a shortage of early-stage capital to move health discoveries from the lab into clinical care. The new partners deepen its ties to Toronto's research hospitals and the Toronto Academic Health Science Network (TAHSN).
Why these partners? UHN describes itself as Canada's leading research hospital, with 1,250 principal investigators, 5,100 research staff and trainees, and $688 million in annual research funding. "These institutions are home to some of Canada's most innovative researchers and clinicians," said Kelly Holman, co-founder and managing director of Genesys Capital.
The backdrop: Entrepreneurs in the University of Toronto community have created more than 1,800 venture-backed startups over the past five years, raising over $27 billion and creating more than 27,000 jobs. Its Health Innovation Hub alone counts more than 340 active ventures.
The signal: Pulling research hospitals into a venture fund as limited partners positions them as commercialization engines, not just centres of care. For Canada's life sciences sector, it is a bet that tighter links between clinical expertise and risk capital can keep homegrown discoveries from stalling before they reach patients.
Read more: morningstar.com
Image credit: V31S70
